MedTrace Logo

Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis

NCT00359736 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2017-11-01

Study results available
· View outcomes & findings →

Summary

Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis (IPF) patients function better. This study will test whether sildenafil improves the ability to exercise in patients with pulmonary fibrosis of unknown cause.

Conditions

  • Alveolitis, Fibrosing
  • Fibrosis, Pulmonary
  • Hypertension, Pulmonary

Interventions

DRUG

sildenafil

Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Robert M Jackson, MD · VA Medical Center, Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-10-31
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00359736 on ClinicalTrials.gov